Enzo Sues Abbott, Becton, Hologic Over Gene-Mapping Patent

An Enzo Biochem Inc. (ENZ) unit sued Abbott Laboratories, Becton Dickinson & Co. and Hologic Inc. (HOLX) for allegedly infringing a patent for gene-mapping in disease diagnostics.

Enzo Life Sciences Inc., based in Farmingdale, New York, is asking for a jury trial, unspecified damages and an order to stop sales of the allegedly infringing products, according to three complaints filed yesterday in federal court in Wilmington, Delaware.

If a court order blocking future infringement isn’t granted, Enzo should be paid “a compulsory ongoing licensing fee” by the defendants, according to the complaint.

Enzo in February sued Roche Diagnostics Corp., Life Technologies Corp. (LIFE) and Gen-Probe Inc. (GPRO) in the same court claiming infringement of the same patent.

The technology involves evaluation of DNA sequences to detect diseases or irregularities such as penicillin resistance in patients with strep infections, gonorrhea or tuberculosis, according to patent papers.

“Abbott doesn’t believe its product infringes this patent and will defend itself accordingly,” said Adelle Infante, a spokeswoman for Abbott Park, Illinois-based Abbott, in an e- mailed statement.

“We’ve received the complaint and are reviewing it,” said Colleen White, a spokeswoman for Franklin Lakes, New Jersey- based Becton Dickinson.

Officials at Bedford, Massachusetts-based Hologic weren’t immediately available to comment on the patent challenge.

The cases are Enzo v. Abbott Laboratories (ABT), 12-cv-00274; Enzo v. Becton Dickinson, 12-cv-00275; and Enzo v. Hologic, 12- cv-00276; U.S. District Court, District of Delaware (Wilmington).

To see the patent, click: 6,992,180.

To contact the reporter on this story: Phil Milford in Wilmington, Delaware, at pmilford@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.